December 9, 2025
1 min read

Its future still in limbo, CSL Seqirus debuts $1B flu shot, antivenom plant in Australia

CSL, which earlier this year shelved plans to put its CSL Seqirus vaccine division up for sale, has opened the doors to a new $1 billion cell-based flu shot and antivenom facility in Melbourne.

Leave a Reply

Your email address will not be published.

Previous Story

Danone named first official yogurt and plant-based beverages sponsor at US Big Ten Conference

Next Story

What is quinoa? And is it actually good for you?

Previous Story

Danone named first official yogurt and plant-based beverages sponsor at US Big Ten Conference

Next Story

What is quinoa? And is it actually good for you?

Latest from Blog

ROFI Drives New Approach to Crop Nutrition

With input costs continuing to pressure farm budgets, some growers are making difficult decisions to reduce fertilizer application rates. While that strategy may ease upfront expenses, it is also accelerating a broader
Go toTop